Zhejiang Huahai Pharmaceutical Co (SHSE:600521) YoY EBITDA Growth : 43.40% (As of Mar. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Zhejiang Huahai Pharmaceutical Co YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Zhejiang Huahai Pharmaceutical Co's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 43.40%.

Zhejiang Huahai Pharmaceutical Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.30.

Zhejiang Huahai Pharmaceutical Co YoY EBITDA Growth Historical Data

The historical data trend for Zhejiang Huahai Pharmaceutical Co's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Huahai Pharmaceutical Co YoY EBITDA Growth Chart

Zhejiang Huahai Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

105.52

24.78

-15.71

55.63

-11.85

Zhejiang Huahai Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial															15.22	-4.47	-26.67	-55.00	43.40

Zhejiang Huahai Pharmaceutical Co YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Zhejiang Huahai Pharmaceutical Co's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(1.45	-	1.645)	/	\| 1.645 \|
=	-11.85 %

Zhejiang Huahai Pharmaceutical Co's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(0.304	-	0.212)	/	\| 0.212 \|
=	43.40 %

Zhejiang Huahai Pharmaceutical Co YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Zhejiang Huahai Pharmaceutical Co's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Huahai Pharmaceutical Co Ltd (SHSE:600521) » Definitions » YoY EBITDA Growth

Traded in Other Exchanges

N/A

Address

Economic Development Zone, Xunqiao Town, Linhai, Taizhou, Zhejiang, CHN, 317024

Website

http://www.huahaipharm.com

Zhejiang Huahai Pharmaceutical Co Ltd provides formulations, active pharmaceutical ingredients, and intermediates in China and internationally. The company also offers pril products, including captopril, enalapril, and lisinopril.

Executives

Chen Bao Hua	Director
Shang Fei	senior management
Du Jun	Director
Su Yan	Director
Chen Dun Yuan	senior management
Li Hong	Director
Guo Si Jia	senior management
Li Min	senior management
Xu Bo	senior management
Wang Jie	senior management
Chen Qi Mao	senior management
Zhang Hong	senior management
Zhang Mei	senior management
Zhu Yong Hua	Directors, senior managers
Wang Yi Hua	senior management

Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Headlines

No Headlines